(Q36946304)

17 August 2017

1 reference

title

Efficacy and safety of insulin detemir (English)

1 reference

17 August 2017

1 reference

Philip Raskin

1

1 reference

17 August 2017

language of work or name

1 reference

1 August 2007

1 reference

Endocrinology and Metabolism Clinics of North America

17 August 2017

published in

1 reference

17 August 2017

volume

36 Suppl 1

1 reference

17 August 2017

page(s)

21-32

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Hypoglycaemia and counterregulation during childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980005-3

7 January 2021

10.1016/S0889-8529(07)80005-3

Identifiers

DOI

1 reference

release_f332zbnkwnb4tjsj3cfnuhntnu

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f332zbnkwnb4tjsj3cfnuhntnu

24 November 2022

mapped directly with Wikidata item

1 reference